These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27322164)

  • 1. Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.
    Aseffa A; Chukwu JN; Vahedi M; Aguwa EN; Bedru A; Mebrahtu T; Ezechi OC; Yimer G; Yamuah LK; Medhin G; Connolly C; Rida W; Aderaye G; Zumla AI; Onyebujoh PC;
    PLoS One; 2016; 11(6):e0157434. PubMed ID: 27322164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.
    Lienhardt C; Cook SV; Burgos M; Yorke-Edwards V; Rigouts L; Anyo G; Kim SJ; Jindani A; Enarson DA; Nunn AJ;
    JAMA; 2011 Apr; 305(14):1415-23. PubMed ID: 21486974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
    Trials; 2020 May; 21(1):383. PubMed ID: 32370774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.
    Bartacek A; Schütt D; Panosch B; Borek M;
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):760-6. PubMed ID: 19460254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
    Al-Shaer MH; Mansour H; Elewa H; Salameh P; Iqbal F
    BMC Infect Dis; 2017 Feb; 17(1):118. PubMed ID: 28152986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.
    Gallardo CR; Rigau Comas D; Valderrama Rodríguez A; Roqué i Figuls M; Parker LA; Caylà J; Bonfill Cosp X
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD009913. PubMed ID: 27186634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
    Padmapriyadarsini C; Bhavani PK; Natrajan M; Ponnuraja C; Kumar H; Gomathy SN; Guleria R; Jawahar SM; Singh M; Balganesh T; Swaminathan S
    BMJ Open; 2019 Mar; 9(3):e024363. PubMed ID: 30826761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar.
    Al-Shaer MH; Elewa H; Alkabab Y; Nazer LH; Heysell SK
    BMC Infect Dis; 2018 Aug; 18(1):384. PubMed ID: 30089476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
    Gopalan N; Santhanakrishnan RK; Palaniappan AN; Menon PA; Lakshman S; Chandrasekaran P; Sivaramakrishnan GN; Reddy D; Kannabiran BP; Agiboth HKK; Krishnamoorthy V; Rathinam S; Chockalingam C; Manoharan T; Ayyamperumal M; Jayanthi N; Satagopan K; Narayanan R; Krishnaraja R; Sathiyavelu S; Kesavamurthy B; Suresh C; Selvachitiram M; Arasan G; Susaimuthu S; Rathinam P; Angamuthu P; Jayabal L; Murali L; Ramachandran R; Tripathy SP; Swaminathan S
    JAMA Intern Med; 2018 Apr; 178(4):485-493. PubMed ID: 29507938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
    Indian J Tuberc; 2007 Apr; 54(2):84-90. PubMed ID: 17575680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study.
    Braga JU; Trajman A
    BMC Infect Dis; 2015 Feb; 15():81. PubMed ID: 25879615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.
    Browne SH; Umlauf A; Tucker AJ; Low J; Moser K; Gonzalez Garcia J; Peloquin CA; Blaschke T; Vaida F; Benson CA
    PLoS Med; 2019 Oct; 16(10):e1002891. PubMed ID: 31584944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.